Five patients completed correlative assessment: 2 exhibited increased High Mobility Group Box 1 (HMGB1), a DAMP molecule associated with the activation of dendritic cells; and 1 patient refractory to combination CTLA-4/PD-1 exhibited increased T cell reactivity to HLA-matched tumor that preceded a durable CR. The gene discussed is HMGB1; the disease is neoplasm.